Amgen's Vectibix approved for colorectal cancer by FDA

27 May 2014
2019_biotech_test_vial_discovery_big

USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, has announced that the US Food and Drug Administration has approved Vectibix (panitumumab) for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with wild-typeKRAS (exon 2) metastatic colorectal cancer (mCRC).

The approval means Vectibix becomes the first biologic to offer a significant survival benefit as a first-line treatment with FOLFOX, one of the most commonly used chemotherapy regimens in the first-line setting for patients with wild-type KRAS mCRC. It also converts the accelerated monotherapy approval to a full approval for Vectibix. The FDA also approved the therascreen KRAS RGQ PCR Kit developed by biotech company Qiagen (therascreen KRAS test) as a companion diagnostic for Vectibix. Amgen also said the approval was a milestone in its biomarker research which helps personalize cancer treatment.

Amgen's personalized approach to oncology treatment

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology